Propeller and GSK expand digital health collaboration

Digital solution provider for respiratory medicine, Propeller Health, is expanding its digital health collaboration with GlaxoSmithKline (GSK) for the improvement of asthma and chronic obstructive pulmonary disease (COPD) management.

With this expansion, the companies will continue in their research and development (R&D) efforts to collect evidence from the Propeller clip-on sensor and software platform used in conjunction with GSK’s respiratory medicines for asthma and COPD.

“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programmes, and for the first time, as part of commercial pilots with GSK outside the US,” said David Van Sickle, CEO and co-founder of Propeller. “Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”

Eric Dube, senior vice president and head, Global Respiratory Franchise GSK, commented: “Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition. We are excited to expand our collaboration with Propeller as a further step in our journey towards achieving connected health systems for people with asthma and COPD.”

This expansion announcement comes after successful CE marking and US FDA 510(k) class II clearance of the Propeller sensor and software program for the ELLIPTA Inhaler, late last year.